Rxsight (NASDAQ: RXST) — Perfil da empresa, notícias e dados financeiros
Rxsight develops customizable intraocular lenses with adjustable power post-implantation to improve post-cataract vision.
Rxsight
Rxsight (NASDAQ:RXST) specializes in the innovative development of customizable intraocular lenses tailored to improve vision after cataract surgery. A standout in post-operative vision correction, their Light Adjustable Lens technology allows eye care professionals to adjust lens power after implantation, ensuring patients achieve optimal visual outcomes. Rxsight's endeavors aim to revolutionize patient experiences in eye care through groundbreaking adjustable lens technology, striving to meet the unique vision needs of individuals worldwide. The company's dedication is rooted in enhancing quality of life through superior visual acuity, moving beyond traditional approaches to address the dynamic nature of vision correction.
Resumo
Operações
Produtos e/ou serviços de Rxsight
- Light Adjustable Lens (LAL) technology allowing patients to customize and optimize their vision after cataract surgery.
- LAL Delivery System, a device designed for the precise implantation of Light Adjustable Lenses.
- UV Light Delivery Device, used to adjust the LAL post-implantation, enabling vision correction customization.
- Advanced intraocular lenses (IOLs) designed for correcting presbyopia and astigmatism, enhancing overall visual outcomes.
- Comprehensive patient education and support services aimed at improving understanding and management of vision correction options.
- Research and development focused on next-generation vision correction solutions, harnessing innovative materials and optical designs.
equipe executiva do Rxsight
- Ilya GoldshlegerChief Operating Officer
- Eric J. WeinbergChief Business Development Officer
- Ronald M. KurtzChief Medical Officer
- Aziz MottiwalaPresident, CEO & Director
- Mark WilterdingChief Financial Officer
- Oliver MoravcevicVice President of Investor Relations
- Jim SchindlerExecutive VP & General Counsel
- Maureen O'ConnellExecutive VP of Clinical & Regulatory Affairs
- Patrick CullenExecutive VP of Quality & Infrastructure Operations
- Adam DasheExecutive Vice President of International
Principais indicadores financeiros
Resultados divulgados pela Rxsight, em USD.
- Cap. de mercado
- 203,8 mi
- Receita (TTM)
- 127,6 mi
- P/L
- —
- LPA (diluído, TTM)
- -1.1
- Dividend yield
- —
- Margem de lucro
- -36.8%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 134,5 mi | -48,2 mi | -38,9 mi | |
| 139,9 mi | -36,9 mi | -27,5 mi | |
| 89,1 mi | -50,1 mi | -48,6 mi | |
| 49 mi | -63,3 mi | -66,8 mi |